retatrutide fda approval status 2025 is everywhere right now and I get asked about it almost daily. Looking at the evidence: Early phase 3 data released by Eli Lilly showed ~28–29% average weight loss at the Retatrutide has not been approved

Who Might Be Suitable for Retatrutide in the Future If approved, eligibility may resemble criteria for current weight loss injectables

Tirzepatide is generally prescribed as a once-per-week self-injection

Improvements in cardiometabolic markers : Participants demonstrated reductions in waist circumference, blood pressure, fasting glucose, and triglyceride levels

Not rotating injection sites can cause lipohypertrophy, which is a buildup of fatty tissue that reduces absorption at that location

These GLP-1 agonists include: Trulicity (dulaglutide) Byetta (exenatide) Bydureon (exenatide extended-release) Victoza (liraglutide) Adlyxin (lixisenatide) Ozempic (semaglutide) Rybelsus (semaglutide) The drugs work best for managing glucose levels when combined with diet and exercise

Despite the side effects and murky insurance coverage, GLP-1s are becoming more common weight loss interventions